Jay Bhattacharya dismissed the test-negative design as 'crap.' The biostatistics literature tells a different story.

Patients who fasted during chemotherapy for ovarian cancer had significantly longer progression-free survival (PFS) compared ...

An official from the US Food and Drug Administration (FDA) on Monday presented three case studies demonstrating how sponsors effectively utilized real-world evidence (RWE) and real-world data (RWD) to ...

Resources for observational comparative research have expanded enormously in recent years to include very large sources of ...

A 10-year follow-up study found that partial meniscectomy did not improve symptoms or knee function when compared with sham ...

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Orchestra BioMed and ...

A BC-led clinical research team is behind a study that could help improve care for critically ill patients in intensive care ...

Mehul V. Raval, MD, MS, discusses newly published findings from the ENRICH-US trial which evaluated the impact of a pediatric ...

Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about metabolism, peptides, and the future of self-driven health ...

Background Research has yielded contradictory results regarding differences in physical fitness and cardiometabolic risk ...

Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus rituximab in refractory RA. Company's AlloNK plus rituximab demonstrated ...

Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst ...